v3.25.2
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 28,827,221 28,001,227 27,870,642 26,988,026
Employee Stock Option        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 11,622,872 13,055,050 11,794,753 13,070,461
Nonvested Restricted Stock Units Outstanding        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 11,722,493 11,174,598 11,163,655 10,757,897
Nonvested Performance-based Restricted Stock Units Outstanding        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 124,976   75,262  
Nonvested Market-based Restricted Stock Units Outstanding Granted        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 5,356,880 3,771,579 4,836,972 3,159,668